Top news of June: Cancer risk, leaf extract, fungal infections, more

Healio has compiled June’s most-read news in dermatology.

A study on the association between a novel, benign nail finding and a cancer-predisposition syndrome topped this month’s list followed by a study on leaf extract supplementation’s ability to improve acne and a report on new cases of a highly contagious, sexually transmitted fungal infection in the U.S.

Novel, benign nail finding linked to syndrome that increases risk for certain cancers

New evidence suggests that a novel, benign nail finding may facilitate the detection of BRCA1-associated protein tumor predisposition syndrome which leaves patients at risk for certain cancers, including cutaneous and internal malignant neoplasms. Read more.

Study finds leaf extract improves acne severity, skin quality in women

Rehmannia glutinosa leaf extract supplementation improved acne severity, skin hydration and the quality of life of women with acne vulgaris with 80% of patients treated with the leaf extract being moved from the moderate to mild severity category vs. 50% of placebo. Read more.

Novel fungal skin infection in US prompts vigilance from dermatologists

In June, NYU Langone Health reported that cases of new forms of a highly contagious fungal infection, found mostly in the genitalia of men who have sex with men, are now being reported in the U.S. Healio spoke with Avrom S. Caplan, MD, assistant professor in the Ronald O. Perelman department of dermatology at NYU Grossman School of Medicine, on how dermatologists should be aware of this infection. Read more.

Triple-combination gel treatment for acne demonstrates efficacy, safety across age groups

According to a post-hoc analysis, fixed-dose clindamycin phosphate 1.2%, adapalene 0.15% and benzoyl peroxide 3.1% gel demonstrated safety and efficacy across all age groups for the treatment of acne. Read more.

FDA expands Klisyri approval for actinic keratosis treatment on larger face, scalp areas

The FDA approved the expanded use area of Klisyri (tirbanibulin) from up to 25 cm² on the face and scalp to up to 100 cm² for the treatment of actinic keratosis, Almirall announced in a press release in June. Read more.

FDA grants breakthrough device designation to AI-powered, diagnostic skin cancer tool

AI continues to make a splash in the medical field with the FDA granting breakthrough device designation to VIO Skin Platform, an AI-powered tool that evaluates suspicious lesions for skin cancer, Enspectra Health announced. Read more.

Oral contraceptive pill usage may be associated with frontal fibrosing alopecia

Women with a history of oral contraceptive pill usage were found to be 1.9 times more at risk for frontal fibrosing alopecia, whereas those with no history of oral contraceptive pill usage were unaffected. Read more.

FDA approves Sofdra gel for primary axillary hyperhidrosis

In June, Botanix Pharmaceuticals announced that the FDA has approved Sofdra (sofpironium) gel 12.45% for the treatment of primary axillary hyperhidrosis in adults and children aged 9 years and older. Read more.

Antihypertensive medications may be linked to lower acne risk

A new study found that antihypertensive medications may lower patients’ risk for developing acne within 5 years of therapy initiation. Read more.

Treatment advancements merit updates to dermatological disqualifiers in the military

In this feature, military members and dermatologists spoke with Healio and expressed the need for the U.S. Department of Defense to update its policies restricting individuals with psoriasis and atopic dermatitis from joining and remaining in the military in lieu of advancing medical treatments. Read more.